Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/18/2025 | $10.00 | Buy | H.C. Wainwright |
5/2/2025 | $11.00 | Strong Buy → Outperform | Raymond James |
3/7/2025 | Buy | Ladenburg Thalmann | |
3/4/2025 | $14.00 | Buy | BTIG Research |
11/11/2024 | $11.00 → $5.50 | Buy → Neutral | H.C. Wainwright |
7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
4/5/2024 | $14.00 | Outperform | Leerink Partners |
12/18/2023 | $12.00 | Strong Buy | Raymond James |
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling